Yes, GLP-1-based therapies are FDA-recommended for weight loss, particularly in individuals with a BMI over 30 or those who did not have success with other weight-loss methods
Why dual agonists may overcome single-receptor tolerance The GIP receptor pathway is distinct from GLP-1 signaling
Prediabetes is defined by A1C between 5.7-6.4% or fasting glucose between 100-125 mg/dL
-- Lofton These social and cultural changes have increased demand, motivating illegal methods to obtain the drugs
At present, the main GLP-1RAs drugs that have been marketed include liraglutide, exenatide, albiglutide and dulaglutide ( The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Osteoporosis Effects of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Osteoporosis Most patients with T2DM have normal bone density, but the risk of fracture is increased
The study found no increase in pancreatic cancer risk with GLP-1RA use, and several sensitivity analyses suggested a modest, non-significant reduction in incidence (Wang et al., 2025)
